- Home
- RCKY vs RAPT Comparison
RCKY vs RAPT Comparison
Compare RCKY & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKY
- RAPT
- Stock Information
- Founded
- RCKY 1932
- RAPT 2015
- Country
- RCKY United States
- RAPT United States
- Employees
- RCKY N/A
- RAPT N/A
- Industry
- RCKY Shoe Manufacturing
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- RCKY Consumer Discretionary
- RAPT Health Care
- Exchange
- RCKY Nasdaq
- RAPT Nasdaq
- Market Cap
- RCKY 196.3M
- RAPT 194.2M
- IPO Year
- RCKY 1993
- RAPT 2019
- Fundamental
- Price
- RCKY $30.27
- RAPT $11.40
- Analyst Decision
- RCKY Buy
- RAPT Buy
- Analyst Count
- RCKY 1
- RAPT 5
- Target Price
- RCKY $40.00
- RAPT $33.60
- AVG Volume (30 Days)
- RCKY 81.7K
- RAPT 104.1K
- Earning Date
- RCKY 07-29-2025
- RAPT 08-07-2025
- Dividend Yield
- RCKY 2.07%
- RAPT N/A
- EPS Growth
- RCKY 24.23
- RAPT N/A
- EPS
- RCKY 2.48
- RAPT N/A
- Revenue
- RCKY $462,328,000.00
- RAPT N/A
- Revenue This Year
- RCKY $7.02
- RAPT N/A
- Revenue Next Year
- RCKY $3.96
- RAPT N/A
- P/E Ratio
- RCKY $12.08
- RAPT N/A
- Revenue Growth
- RCKY N/A
- RAPT N/A
- 52 Week Low
- RCKY $11.93
- RAPT $5.67
- 52 Week High
- RCKY $33.04
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- RCKY 70.80
- RAPT 53.89
- Support Level
- RCKY $25.76
- RAPT $10.06
- Resistance Level
- RCKY $31.30
- RAPT $11.58
- Average True Range (ATR)
- RCKY 1.08
- RAPT 0.93
- MACD
- RCKY 0.26
- RAPT -0.02
- Stochastic Oscillator
- RCKY 84.75
- RAPT 71.43
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.